Reata Pharmaceuticals, Inc. is a biopharmaceutical company focused on translating promising technologies into successful marketed drugs to treat intractable diseases.
Reata's strategy is to advance multiple drug development opportunities rapidly to human proof of concept on a single management and technology infrastructure. This has allowed the company to effectively manage risks and to develop drugs in a capital and time efficient manner. With this strategy, the company has advanced two breakthrough drugs to advanced clinical trials, having achieved proof of concept. |
 |
6.18.2008 - Reata Expands Executive Team to Support Advancing Clinical Programs |
| |
Reata Pharmaceuticals, Inc. announced a substantial expansion of its executive team to take advantage of opportunities from its advancing clinical and preclinical pipelines. Seasoned executives have been added to the team in the areas of clinical development, regulatory affairs, and business development.
|
|
6.1.2008 - ASCO: First-In-Man Study of RTA 402 Yields Promising Results in Patients with Advanced Cancers |
| |
Reata Pharmaceuticals, Inc. announced results from a first-in-man study of RTA 402 in patients with advanced cancers, presented in an oral session at the annual meeting of the American Society for Clinical Oncology. RTA 402 is the clinical lead from Reata's Antioxidant Inflammation Modulators (AIMs), a new and highly promising category of drugs for the treatment of cancer and inflammation. One of the study's Principal Investigators, Dr. David Hong from the University of Texas M. D. Anderson Cancer Center, presented data showing that RTA 402 had an excellent safety profile and provided a clinical benefit in a significant percentage of patients. Investigators also confirmed that the drug was active against its biological targets, NF-kappa B and STAT3. These pro-inflammatory transcription factors promote tumor growth, angiogenesis, invasion, metastasis, and resistance to therapy. Overall, RTA 402 showed a profile of disease control and tumor reduction comparable or superior to any recently approved targeted therapy in a Phase I patient population and a markedly superior side effect profile.
|
|
5.27.2008 - Reata to Present at FBR Capital Markets Investor Conference in NYC on May 29 |
| |
Reata Pharmaceuticals, Inc. announces that its CEO, Warren Huff, will be presenting a company overview on Thursday, May 29, 2008 at the FBR Capital Markets 12th Annual Spring Investor Conference. This event is being held at the Grand Hyatt hotel in New York, New York. Mr. Huff's presentation is scheduled for 2:00 pm Eastern Time. The presentation will focus on Reata's two franchise technologies: its AIM platform of novel, broad-spectrum anti-inflammatory agents and its protein folding discovery platform. It will also highlight a number of upcoming Phase 2 data events with Reata's two lead compounds.
|
|
5.22.2008 - 10 New Papers Published on Anti-Cancer Effects of Reata AIMs |
| |
Reata Pharmaceuticals, Inc. announced the publication of 10 separate peer-reviewed papers supporting the use of its Antioxidant Inflammation Modulators (AIMs) in cancer patients. These papers reflect work conducted at leading academic institutions including Dartmouth Medical School, The Burnham Institute, and the Dana-Farber Cancer Institute. Collectively, they further elucidate the novel mechanism of action of the AIMs in cancer, demonstrate effects in a broad array of tumor types, and show consistent activity across multiple structural analogs.
|
|
5.21.2008 - Phase 1 Cancer Results with RTA 402 Scheduled for Oral Presentation at 2008 ASCO |
| |
Results of a Phase 1 clinical trial of RTA 402 in patients with advanced cancers was selected for an oral presentation at the 2008 annual meeting of the American Society of Clinical Oncologists.
The presentation is scheduled for 8:15 a.m. on Sunday, June 1, 2008. The abstract is now available on the ASCO web site:
http://www.abstract.asco.org/AbstView_55_35471.html
Updated data from the clinical trial will be presented.
|
 |
| |
|
|
 Reata has amassed a rich pipeline of drug development opportunities. The company is pursuing four Phase 2 programs with our two lead molecules. |
| |
|
 |
is an oral, non-toxic Antioxidant Inflammation Modulator (AIM) with potential to treat a broad range of inflammation-related diseases. Phase 2 programs are underway in cancer, renal disease, and autoimmune disease. |
|
|
, also in Phase 2 trials, has produced clinical benefits in patients with deadly brain tumors as well as tumors that have spread to the central nervous system.
Reata is also developing a number of earlier stage products, including other orally available AIM agents with strong potential to treat CNS disease and other inflammatory conditions. Additionally, the company is actively discovering new drug candidates through our best-in-class protein folding discovery platform. |
|
| |
|
|
